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ABSTRACT
Objective. We evaluated a hepatitis C virus (HCV) testing and linkage-to-care 
post-release program among detainees of small- to medium-sized jails in North 
Carolina and South Carolina as part of the Hepatitis Testing and Linkage to 
Care initiative. 
Methods. An HCV testing and linkage-to-care program was implemented in 
selected jails in North Carolina and South Carolina from December 2012 to 
March 2014. Health-care workers not affiliated with the jails conducted HCV 
antibody (anti-HCV) and HCV ribonucleic acid (RNA) testing and linkage-to-care 
activities. The North Carolina jail provided universal opt-out testing for HCV; 
South Carolina jails initially targeted high-risk individuals before expanding to 
routine testing. 
Results. Of 669 detainees tested for HCV in North Carolina, 88 (13.2%) 
tested anti-HCV positive, of whom 81 (92.0%) received an HCV RNA test, 66 
(81.5%) of whom tested HCV RNA positive (i.e., currently infected). Of the 66 
detainees with current HCV infection, 18 were referred to HCV medical care 
post-release and 10 attended their first appointment. Of 224 detainees tested 
for HCV in South Carolina, 18 (8.0%) tested anti-HCV positive, of whom 13 
received an HCV RNA test. Nine of 13 detainees tested HCV RNA positive, 
seven detainees were referred to post-release medical care, and two detainees 
attended their first appointment. Overall, 106 of 893 (11.9%) detainees were 
anti-HCV positive.
Conclusion. This study demonstrated that HCV testing, identification of 
infection, and linkage to care are feasible among jail populations. The rate of 
anti-HCV positivity was lower than that found in national studies of incarcerated 
populations, suggesting that HCV infection prevalence in jails may vary across 
U.S. states or regions. 
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Hepatitis C is the most common blood-borne infec-
tion in the United States, with an estimated 1.6% of 
the U.S. population testing positive for the hepatitis 
C virus (HCV) antibody (anti-HCV).1 Approximately 
three-quarters of people with HCV infection develop 
chronic infection, the leading cause of hepatocellular 
carcinoma and liver-related mortality.2,3 Of those with 
chronic HCV infection, only about half are aware of 
their infection.4 Furthermore, in a recent study of four 
of the largest U.S. health-care systems, 3,570 of 5,860 
(61%) anti-HCV-positive people received a confirmatory 
HCV ribonucleic acid (RNA) test (indicating chronic 
infection) as recommended.5 Effective treatment can 
prevent HCV-related morbidity and mortality if those 
with chronic HCV infection are identified and receive 
appropriate medical management and treatment.6 
Because 10 million people are detained in U.S. 
jails or imprisoned annually,7 and recent estimates 
have found that about 23% of incarcerated people are 
anti-HCV positive, a substantial proportion of the 4.6 
million anti-HCV-positive Americans8 may be currently 
incarcerated. Although all U.S. correctional facilities 
must provide basic medical care,9 access to health care 
often ends after release into the community.10 Identi-
fying HCV infections within correctional settings and 
linking infected inmates to medical care may prevent 
new infections and help tens of thousands of infected 
people avoid HCV-associated morbidity and mortality.11 
Correctional facilities include short-term jails, which 
detain people for about 2–5 days,12 and prisons, which 
house people who have been convicted of a felony 
for $1 year. The administrative organization of cor-
rectional facilities differs, and screening programs 
in a small jail may not be the same or as feasible as 
one in a large jail. Although several studies of hepati-
tis C in correctional settings have been conducted in 
large prisons or jails housing .1,000 detainees, few 
have involved medium- to small-sized jails housing 
,99 inmates, which represent 59% of U.S. jails.13 To 
better understand the problem of HCV infection in 
the correctional population nationally, smaller jails 
and prisons need to be examined. We evaluated an 
HCV testing program in small- to medium-sized jails 
in North Carolina and South Carolina funded by the 
Hepatitis Testing and Linkage to Care (HepTLC) initia-
tive, which promoted viral hepatitis B and hepatitis C 
screening, posttest counseling, and linkage to care at 
34 U.S. sites from 2012 to 2014.14 We assessed whether 
or not detainees who were anti-HCV positive received 
HCV RNA testing, and whether or not those who were 
HCV RNA positive (i.e., currently infected) attended 
their first posttest medical appointment within a 90-day 
follow-up period. 
METHODS
Project sites
In North Carolina, the Durham County Department of 
Public Health conducted testing at the state’s 736-bed 
Durham County Jail. In 2012, the medium-sized jail 
had 8,673 admissions. Turnover in this population is 
high, with half of detainees staying fewer than two days, 
and most of the general-population inmates includ-
ing young African American men (Unpublished data, 
Durham County Department of Public Health, 2014). 
In South Carolina, HopeHealth, Inc. conducted test-
ing in four small- to medium-sized jails: the Florence 
County Detention Center, Orangeburg County Jail, 
Marion Jail, and Darlington Jail. The sites reported 
capacities ranging from 96 to 512 beds. One of the 
jails reported that 65% of the total jail population had 
an average length of stay of ,2 days. Similar to the 
Durham County Jail, the South Carolina general jail 
population comprised predominately young African 
American men (Unpublished data, HopeHealth, Inc., 
2014). A testing model15 was implemented in all South 
Carolina jails whereby health-care workers who were 
separate from the corrections staff (i.e., parallel staff 
members) conducted HCV testing alongside the jails’ 
usual health-care staff members. This model contrasts 
with an integrated system15,16 in which correctional 
health-care staff members perform testing as part of 
routine clinical care. The parallel staff members linked 
detainees identified with current HCV infection to 
community health-care services to receive treatment 
after release from jail. 
North Carolina program
The Durham County Department of Public Health 
conducted HCV testing in North Carolina from Decem-
ber 2012 to March 2014. During the limited hours of 
their visits, personnel offered opt-out HCV testing to 
detainees in male and female housing units, regard-
less of birth year, injection drug use, and/or human 
immunodeficiency virus (HIV) infection. The health 
department also provided daily educational sessions 
(i.e., individual and group) in the housing units, fol-
lowed by an offer of confidential testing for detainees 
not presenting proof of recent HCV testing in the jail. 
Detainees interested in the educational program were 
asked to provide written consent and then to complete 
a survey of risk factors and basic demographics. 
Beginning in August 2013, using funding provided 
by the state and earmarked for minority health, staff 
members from the Durham County Department of 
Public Health began simultaneously drawing two vials of 
blood from minority (i.e., African American, Hispanic) 
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detainees. The first blood specimen was tested for anti-
HCV. If positive, the second specimen was tested for 
HCV RNA. Non-minority detainees were offered HCV 
RNA testing via a second blood draw after receiving 
a reactive anti-HCV test result. Two health educators 
were trained in phlebotomy to provide anti-HCV and 
confirmatory HCV RNA testing, and provide posttest 
counseling to HCV RNA-positive detainees. Referrals 
were made to the patient navigator, who met with the 
detainees to help with their transition to HCV-related 
care in the community. Patient navigators located 
detainees who were released from jail prior to receiv-
ing their test results and provided additional posttest 
counseling on the disease, alcohol reduction, risk 
reduction, and linkage to HCV-related clinical care 
upon release. 
During the project’s initial phases, participants were 
referred to Duke University for their first medical 
appointment post-release. Later in the project period, 
individuals were referred to either the clinic at the 
University of North Carolina (UNC), Chapel Hill, or to 
a local physician who would schedule an appointment 
with them shortly after reentry into the community. 
This change was necessary because Duke University 
was able to accept only uninsured patients residing in 
Durham County, while UNC, as a state hospital, did 
not have a residence restriction. From September 2013 
to March 2014, the state of North Carolina provided 
separate funding to supplement anti-HCV testing in 
the jail. During this later phase, all anti-HCV-positive 
inmates were integrated into the linkage-to-care por-
tion of the program, thus providing them with access 
to HCV RNA testing and linkage-to-care services. 
South Carolina program
In South Carolina, HopeHealth, Inc. conducted HCV 
testing with parallel staff members from January to 
September 2013. Initially, the South Carolina program 
targeted detainees born between 1945 and 1965 (i.e., 
the birth cohort)17 or those who had obtained tattoos 
in non-professional or unregulated settings. Although 
people who inject drugs were not specifically targeted, 
risk-factor information was collected for every detainee 
assessed in the program. Seropositive detainees would 
then have a second vial of blood drawn for HCV RNA 
testing. Testing frequency varied based on how often 
the parallel staff members visited the jail. 
 HopeHealth, Inc. staff members visited Marion 
Jail monthly and the Florence County and Darlington 
jails bimonthly to conduct testing and linkage-to-care 
services. The Orangeburg County Jail also received 
monthly visits; however, after low participation rates, 
HopeHealth Orangeburg reevaluated testing policies 
and expanded testing to bimonthly. Testing was also 
expanded to include other detainees in addition to 
those born between 1945 and 1965 or with tattoos 
from unlicensed settings. Prior to release, detainees 
at all jails received anti-HCV test results and, when 
available, HCV RNA test results. Detainees who were 
identified with current HCV infection received HCV-
related education as posttest counseling from Hope-
Health staff members. Detainees in Marion, Florence, 
and Darlington jails who were currently infected were 
referred to HopeHealth Florence, a federally qualified 
health center, to receive HCV-related medical care. 
Parallel staff members assigned to the Orangeburg jail 
set up appointments for detainees with current HCV 
infection to see a health-care provider and receive 
medical care after their release from jail. 
Data management and analysis
Data were collected and entered into EvaluationWeb®,18 
an Internet-based database customized for the HepTLC 
initiative. Each month from December 2012 through 
June 2014, staff members from the Durham County 
Department of Public Health and HopeHealth, Inc. 
submitted testing data (i.e., anti-HCV and HCV RNA 
test results) and follow-up information to allow this 
information to be included for those detainees entering 
care after March 2014. Follow-up information consisted 
of the number of detainees who received test results, 
participated in posttest counseling, were referred to 
care, and attended their first medical appointment 
post-release.
RESULTS
North Carolina program outcomes
The Durham County program tested 669 detainees 
for anti-HCV during 16 months in a jail that averages 
723 monthly admissions (i.e., 11,500 admissions in 16 
months), representing 5.6% of all people admitted. A 
total of 88 of 669 (13.2%) detainees who were tested 
were anti-HCV positive, of whom 81 (92.0%) were 
tested for HCV RNA. Of the 66 (81.5%) HCV RNA-
positive detainees, 18 were referred to medical care 
post-release and 10 attended their first appointment 
(Table 1). 
Among anti-HCV-positive detainees, 17 of 21 
(81.0%) women and 49 of 67 (73.1%) men were HCV 
RNA positive. The prevalence of current infection was 
76.5% (26/34) among non-Hispanic white detainees, 
75.5% (37/49) among non-Hispanic black detainees, 
and 33.3% (1/3) among Hispanic detainees (Table 2). 
The median age was 33.5 years (interquartile range 
[IQR] 5 23–39) for detainees who were tested, 43.0 
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years (IQR532–51) for those who were anti-HCV 
positive, and 46.0 years (IQR535–52) for those with 
current infection (Table 2). 
Among the 77 birth-cohort detainees tested, 35 
(45.5%) were anti-HCV positive, of whom 31 (88.6%) 
were HCV RNA positive. Among 73 detainees reporting 
a history of drug use and/or HIV infection, regardless 
of birth year, 43 (58.9%) were anti-HCV positive, of 
whom 32 (74.4%) were currently infected with HCV. 
Of the 568 people without reported risk factors, regard-
less of birth year, 44 (7.7%) were anti-HCV-positive, of 
whom 34 (77.3%) had current HCV infection (Table 2). 
South Carolina program outcomes
HopeHealth, Inc. tested 224 detainees for anti-HCV in 
the four participating South Carolina jails, of whom 18 
(8.0%) were anti-HCV positive, 13 received an HCV 
RNA test, and nine tested HCV RNA positive. Of the 
nine detainees with current HCV infection, seven were 
referred to medical care and two attended their first 
medical appointment during a 90-day observation 
period (Table 1). 
Five of the 68 non-Hispanic white detainees and 
three of the 146 non-Hispanic black detainees had 
current HCV infection (Table 2). The median age was 
33.5 years (IQR527–45) for detainees tested, 38.5 years 
(IQR532–46) for anti-HCV-positive detainees, and 45.0 
years (IQR539–52) for HCV RNA-positive detainees. A 
total of 53 detainees self-reported having a risk factor 
for HCV infection at the time of enrollment, regardless 
of birth year; of these, 12 were anti-HCV positive and 
five were HCV RNA positive (Table 2). 
DISCUSSION 
This project demonstrated that HCV testing and 
linkage-to-care services can be conducted in a jail by 
non-correctional staff members in parallel with correc-
tional health-care program staff members (i.e., parallel 
testing). To our knowledge, this is the largest study 
yet of parallel testing for HCV in a southeastern jail. 
Voluntary HCV testing in North Carolina and South 
Carolina jails identified a relatively high prevalence 
of HCV infection among detainees compared with 
estimates (i.e., 1.0%) in the general U.S. population,4 
although the 11.9% overall seroprevalence in these jail 
populations was lower than a recently published sero-
prevalence estimate (i.e., 23.1%) among incarcerated 
people nationally.8 That national estimate reported by 
Edlin et al. was based on older studies with heightened 
estimates of prevalence compared with the current 
national prevalence for correctional institutions. Our 
lower prevalence supports a surveillance study by 
Varan et al., which showed that HCV prevalence in 
correctional populations is not geographically uniform 
and can vary by state and region; furthermore, HCV 
prevalence has declined in recent years.10 
Through this study, we observed a higher prevalence 
of current HCV infection for people born between 
1945 and 1965 in correctional settings, similar to the 
prevalence pattern found among the birth cohort in 
the general population. Targeted testing of the birth 
cohort and other people at risk (i.e., tattoo recipients) 
at the start of the program in South Carolina might 
have elevated the percentage who were anti-HCV posi-
tive; if this were the case, the true prevalence in the 
South Carolina jails may have been lower than 8.0%. 
Also, this study did not show how the parallel testing 
model, which tested 5.8% (669/11,500) of admissions 
Table 1. Care cascade among detainees tested for hepatitis C as part of the Hepatitis Testing and Linkage to Care 
(HepTLC) initiative, by testing program, North Carolina and South Carolina jails, December 2012 to March 2014
Location
Number 
tested for 
anti-HCV
Number 
testing anti-
HCV positive 
(percent)a
Number 
tested for 
HCV RNA 
(percent of 
anti-HCV 
positive)a
Number 
testing HCV 
RNA positive 
(percent)a
Number 
receiving 
test results 
(percent)a
Number 
receiving 
posttest 
counseling 
(percent)a
Number 
referred to 
medical  
care 
(percent)a
Number 
attending 
first medical 
appointment 
(percent)a
Total 893 106 (11.9) 94 (88.7) 75 (79.8) 57 (76.0) 58 (77.3) 25 (33.3) 12 (48.0)
North Carolina 669 88 (13.2) 81 (92.0) 66 (81.5) 50 (75.8) 50 (75.8) 18 (27.3) 10 (55.6)
South Carolina 224 18 (8.0) 13 (72.2) 9 (69.2) 7 (77.8) 8 (88.9) 7 (77.8) 2 (28.6)
aPercentages are row percentages.
anti-HCV 5 antibody to hepatitis C virus
HCV 5 hepatitis C virus
RNA 5 ribonucleic acid
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in the Durham County Jail, might compare with an 
integrated testing strategy; however, a program that 
involved rapid HIV testing in an Atlanta, Georgia, jail 
found that integrated serological testing permitted 
staff members to test 56.2% (17,035/30,316) of all 
detainees.16
In a study of the Pennsylvania Department of Cor-
rections, Larney et al. demonstrated that as time passes, 
targeting the 1945–1965 birth cohort alone may fail to 
find an increasing percentage of hepatitis C infection 
among younger prisoners.19 The declining contribution 
from the birth cohort is similar to trends that have been 
found in non-correctional settings where, in 2006, 36% 
of incident hepatitis C cases occurred among people 
,30 years of age and rose to 49% from 2007 to 2012.20,21 
The increase in new cases of HCV infection among 
young people has been attributed to the emergence 
of younger injection drug users who have transitioned 
from oral to injection opioid use.20 People ,30 years 
of age comprise a large proportion of the new cases of 
HCV infection among injection drug users.22 
Because behaviors that place people at risk for HCV 
infection (e.g., injection drug use) are associated with 
incarceration, correctional facilities are strategic venues 
for HCV testing and linkage to care.19,23–25 We found 
that detainees with self-reported risk factors and those 
born between 1945 and 1965 had a higher prevalence 
of HCV infection than those who had no risk factors 
and were not baby boomers. Nevertheless, consider-
ably fewer detainees might have been detected had 
the program incorporated a strategy of testing only 
those in the birth cohort or those reporting high-risk 
behavior. If systems cannot implement routine testing 
of all detainees, as recommended by the U.S.  Preventive 
Table 2. Characteristics of detainees testing anti-HCV positive and HCV RNA positive during the Hepatitis Testing 
and Linkage to Care (HepTLC) initiative, North Carolina and South Carolina jails, December 2012 to March 2014 
Characteristic
North Carolina jail South Carolina jails
Number 
tested for 
anti-HCV
Number 
testing anti-
HCV positive 
(percent)a
Number testing 
HCV RNA  
positive  
(percent)a
Number 
tested for 
anti-HCV
Number  
testing anti- 
HCV positive 
(percent)a
Number testing  
HCV RNA  
positive  
(percent)a
Total 669 88 (13.2) 66 (75.0) 224 18 (8.0) 9 (50.0)
Sex
 Female 134 21 (15.7) 17 (81.0) 34 6 (17.6) 1 (16.7)
 Male 533 67 (12.6) 49 (73.1) 190 12 (6.3) 8 (66.7)
 Transgender 2 0 (0.0) 0 (0.0) 0 0 (0.0) 0 (0.0)
Age, in years
 20–29 296 17 (5.7) 8 (47.1) 2 1 (50.0) 0 (0.0)
 30–39 173 18 (10.4) 12 (66.7) 61 8 (13.1) 2 (25.0)
 40–49 110 18 (16.4) 15 (83.3) 81 5 (6.2) 3 (60.0)
 50–59 56 31 (55.4) 27 (87.1) 47 4 (8.5) 4 (100.0)
 $60 12 4 (33.3) 4 (100.0) 30 0 (0.0) 0 (0.0)
 Not reported 22 0 (0.0) 0 (0.0) 3 0 (0.0) 0 (0.0)
Race/ethnicity
 Non-Hispanic black/African American 477 49 (10.3) 37 (75.5) 146 3 (2.1) 3 (100.0)
 Non-Hispanic white 116 34 (29.3) 26 (76.5) 68 13 (19.1) 5 (38.5)
 Hispanic 42 3 (7.1) 1 (33.3) 3 1 (33.3) 1 (100.0)
 Not reported 34 2 (5.9) 2 (100.0) 7 1 (14.2) 0 (0.0)
Birth cohort vs. non-birth cohort
 1945–1965 77 35 (45.5) 31 (88.6) 40 4 (10.0) 4 (100.0)
 Other 592 53 (9.0) 35 (66.0) 184 14 (7.6) 5 (35.7)
Reported risk factorsb
 Risk factors 73 43 (58.9) 32 (74.4) 53 12 (22.6) 5 (41.7)
 No risk factors 568 44 (7.7) 34 (77.3) 171 6 (3.5) 4 (66.7)
 Not reported 28 1 (3.6) 0 (0.0) 0 0 (0.0) 0 (0.0)
aPercentages are row percentages.
bRisk is defined as any history of injection drug use and/or human immunodeficiency virus positive.
anti-HCV 5 antibody to hepatitis C virus
HCV 5 hepatitis C virus
RNA 5 ribonucleic acid
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Services Task Force guidelines,26 future studies in cor-
rectional institutions will be needed to gain a better 
understanding of the characteristics of those most likely 
to be infected with HCV within these settings who can 
then be targeted for testing. 
To reduce both HCV transmission and complications 
of infection, all people with HCV infection need to be 
identified and linked to medical care. Those with cur-
rent infection have a higher likelihood of morbidity 
and mortality. Identifying these individuals and linking 
them to care after their release is an important, yet 
challenging, task. In the future, HCV antigen testing 
could be more effective than anti-HCV testing for 
detecting viremia with a reflex to polymerase chain 
reaction testing, especially when conducting a second 
blood draw is inconvenient. 
Efforts are also needed to ensure that currently 
infected detainees have a post-release medical appoint-
ment scheduled prior to their release and that atten-
dance at these appointments is actively supported (i.e., 
via travel assistance and follow-up reminders). The 
first post-release medical appointment enables the 
detainee and his or her clinician to make an informed 
decision regarding the next steps in care, which could 
include counseling for alcohol use and risk reduction 
to prevent transmission to others, employing a wait-and-
watch strategy to monitor the infection, or beginning 
treatment. More research is needed to determine the 
societal cost-effectiveness of HCV testing in jails.
Limitations
This study was subject to several limitations. The overall 
HCV infection prevalence that we found in these jails 
could have been overestimated because the program in 
South Carolina began by targeting those at higher risk 
of HCV infection, specifically detainees born between 
1945 and 1965 and those with tattoos that were applied 
in non-professional and unregulated settings. Neverthe-
less, the HCV seroprevalence in these jails was similar 
to the 7.5% HCV seroprevalence found in an Atlanta 
jail.9 Furthermore, because of programmatic changes 
during the evaluation process, we could not discern 
which components of the programs across the two 
states were most responsible for success in identifying 
people who were anti-HCV positive, who completed 
diagnostic testing, and who were linked to care. 
Additionally, risk-factor data were collected through 
detainee self-report during enrollment. As such, the 
number of detainees with risk factors for HCV infec-
tion was potentially underrepresented because of 
fear of self-incrimination if revealing illicit activity 
resulted in additional charges being filed. Although 
the programs prioritized people who were unaware of 
their status, they did not collect information on the 
percentage of people testing positive or negative who 
were previously aware of their infection status. Finally, 
the number of detainees who were eventually referred 
to care and attended their first medical appointment 
may have been underreported because detainees may 
have had jail stays .90 days post-HCV diagnosis, the 
observational period in this study. 
As a demonstration project, we did not collect data 
on people who were not tested or the reason why they 
did not test. In the absence of state health departments 
compiling complete name-based registries of people 
who are HCV infected, we could not determine what 
percentage of diagnoses were new and the length of 
time those who were viremic were infected. Neverthe-
less, the methods used were unlikely to result in a 
profound underestimate of the HCV prevalence for 
the population passing through these jails. Using preva-
lence as a proxy for positivity rate was also a limitation. 
CONCLUSION
Our project demonstrated that HCV testing, identifica-
tion of infection, and linkage to care are feasible in 
detainee populations. A substantial number of people 
with current HCV infection are incarcerated in cor-
rectional facilities in the southeastern United States. 
Future research might explore how individuals fall out 
of the HCV care cascade (i.e., from testing to medical 
care) and if gaps in the cascade vary by region. 
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